Investor's Business Daily on MSN
Gene editors, including powerhouse Beam Therapeutics, diverge on legal battle
Prime Medicine won a legal battle with Beam Therapeutics on Wednesday. Prime shares jumped while Beam stock skidded.
Prime Medicine, Inc. wins arbitration vs. Beam Therapeutics Inc., advancing PM647 for AATD. Read more on PRME and BEAM stocks ...
A Beam Therapeutics gene-editing therapy designed to fix a mutation at the root of a rare liver protein deficiency now has early signs of efficacy along with safety data that ease some concerns about ...
Prime Medicine has come out ahead in its patent dispute with fellow gene editing biotech Beam Therapeutics, after a panel of ...
This story is republished from STAT, the health and medicine news site that’s a partner to the Globe. Sign up for STAT’s free ...
“PKU affects approximately 20,000 people in the U.S., with significant unmet need for therapies that address the underlying cause of disease,” said Giuseppe Ciaramella, Ph.D., president of Beam. “FDA ...
An arbitration panel ruled Prime did not violate an agreement with Beam when it developed PM647, for which Prime plans to launch a clinical trial.
Biotech stocks continued to surge on Wednesday after two scientists responsible for gene-editing tool CRISPR received this year’s Nobel Prize for Chemistry. CRISPR-powered stocks Intellia Therapeutics ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results